Mathematicians present the Nopertedro: a Rupert property solid that broke an old myth by preventing one copy from passing ...

Leopoly releases Shapelab Max 2026, updating its VR and desktop sculpting tool with a redesigned gizmo system and a new ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Department of Inorganic Chemistry, Indian Association for the Cultivation of Science, Raja S. C. Mullick Road, Kolkata, 700032, India, and Department of Chemistry ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know. Vertex Pharmaceuticals beat analysts’ revenue ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...